On 10th day after testing positive, 4 1/2 days after finishing course of paxlovid, cold-like symptoms have returned.; On 10th day after testing positive, 4 1/2 days after finishing course of paxlovid, cold-like symptoms have returned.; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (On 10th day after testing positive, 4 1/2 days after finishing course of paxlovid, cold-like symptoms have returned.) and NASOPHARYNGITIS (On 10th day after testing positive, 4 1/2 days after finishing course of paxlovid, cold-like symptoms have returned.) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 065K21A) for COVID-19 vaccination.     Concurrent medical conditions included Type 1 diabetes mellitus (Type 1 diabetes, well controlled with insulin, pump, and CGM). Concomitant products included METFORMIN and CELECOXIB (CELEBREX) for an unknown indication.    On 14-Apr-2022 at 6:00 PM, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (On 10th day after testing positive, 4 1/2 days after finishing course of paxlovid, cold-like symptoms have returned.). On 14-May-2022 at 10:00 PM, the patient experienced NASOPHARYNGITIS (On 10th day after testing positive, 4 1/2 days after finishing course of paxlovid, cold-like symptoms have returned.). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 06-May-2022 to 10-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (On 10th day after testing positive, 4 1/2 days after finishing course of paxlovid, cold-like symptoms have returned.) outcome was unknown and NASOPHARYNGITIS (On 10th day after testing positive, 4 1/2 days after finishing course of paxlovid, cold-like symptoms have returned.) was resolving. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-May-2022, SARS-CoV-2 test: positive (Positive) Positive.         Patient's race was reported.  CC: This spontaneous case concerns a 54-year-old male patient, with a relevant history of Type I diabetes mellitus, who experienced the unexpected, non-serious Adverse Event of Special Interest of COVID-19, which occurred 20 days after the fourth dose of mRNA-1273 vaccine administration. On 10th day after testing positive, 4 1/2 days after finishing course of Paxlovid, cold-like symptoms (non-serious event Nasopharyngitis) have returned. The diagnosis of COVID-19 was supported by SARS-CoV-2 test which was positive. The ongoing COVID-19 pandemic and underlying  history of type I diabetes mellitus could be confounders for the event. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 54-year-old male patient, with a relevant history of Type I diabetes mellitus, who experienced the unexpected, non-serious Adverse Event of Special Interest of COVID-19, which occurred 20 days after the fourth dose of mRNA-1273 vaccine administration. On 10th day after testing positive, 4 1/2 days after finishing course of Paxlovid, cold-like symptoms (non-serious event Nasopharyngitis) have returned. The diagnosis of COVID-19 was supported by SARS-CoV-2 test which was positive. The ongoing COVID-19 pandemic and underlying  history of type I diabetes mellitus could be confounders for the event. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.